[Primary cutaneous follicle centre lymphoma: report of a case].
Yin-fang
YF
Rong
Lin-ming
LM
He
E-mail: shengyongzh@126.com.
Yong-sheng
YS
Zhang
Yi-zhong
YZ
Feng
D018951:Antigens, CD20 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000378:metabolism / Q000473:pathology; D051925:CD79 Antigens / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D051560:Proto-Oncogene Proteins c-bcl-6; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D014750:Vincristine / Q000627:therapeutic use
D018951:Antigens, CD20; C084103:BCL6 protein, human; D051925:CD79 Antigens; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone